Experimental combo shows promise for Tough-to-Treat leukemia
NCT ID NCT02005289
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of two drugs—MOR00208 (an antibody that targets cancer cells) and lenalidomide (which boosts the immune system)—in 41 people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or prolymphocytic leukemia (PLL). Some participants had not been treated before, while others had relapsed or not responded to prior therapies, including ibrutinib. The goal was to see how many patients achieved a significant reduction in cancer. The study also included a small pilot group with Richter's transformation, a more aggressive form of the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MOR00208 (a monoclonal antibody) and lenalidomide (an immune-modulating drug)
What this could lead to
If successful, this combination could offer a new treatment option for people with hard-to-treat CLL, SLL, or PLL, including those who have stopped responding to other therapies.
What could go wrong
This is a small, early-phase study (41 participants) with no control group, so results may not apply broadly. Side effects from the combination are possible, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States